Ken Griffin
BBOT

Ken Griffin’s BridgeBio Oncology BBOT Stock Holding History

Ken Griffin’s Portfolio BBOT Stock Details BBOT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$19.9M Buy
2,617,827
+89,065
+4% +$743K ﹤0.01% 2591
2026
Q1 		$22.6M Sell
2,528,762
-1,562
-0.1% -$16.8K ﹤0.01% 2187
2025
Q4 		$31.7M Sell
2,530,324
-7,817
-0.3% -$94.7K ﹤0.01% 1843
2025
Q3 		$29.4M Buy
2,538,141
+1,110,940
+78% +$11.6M ﹤0.01% 1896
2025
Q2 		$15.2M Buy
1,427,201
+15,241
+1% +$165K ﹤0.01% 2491
2025
Q1 		$16M Buy
1,411,960
+72,290
+5% +$777K ﹤0.01% 2290
2024
Q4 		$14.1M Buy
1,339,670
+7,020
+0.5% +$73.9K ﹤0.01% 2563
2024
Q3 		$13.9M Buy
1,332,650
+142
+0% +$1.47K ﹤0.01% 2470
2024
Q2 		$13.6M Buy
1,332,508
+55
+0% +$566 ﹤0.01% 2414
2024
Q1 		$13.8M Buy
+1,332,453
New +$13.8M ﹤0.01% 2507

Other funds holding BBOT

CAM
Cormorant Asset Management Boston, Massachusetts $1.95B AUM 773.9% 1-Year Est. Return
OFM
Omega Fund Management Boston, Massachusetts $186M AUM 155.23% 1-Year Est. Return
AI
Alphabet Inc Mountain View, California $99.1B AUM 124.46% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.06B AUM 215.32% 1-Year Est. Return
ES
Enavate Sciences Menlo Park, California $345M AUM 134.64% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.72B AUM 106.92% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
AC
Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Ken Griffin's BBOT Position: Q2 2026 in Review

Ken Griffin increased its BridgeBio Oncology (BBOT) stake by 3.5% in Q2 2026, buying an estimated $743K and bringing the position to 2,617,827 shares worth $19.9M. The position accounts for ﹤0.01% of the portfolio, ranked #2591.

Ken Griffin first reported a position in BBOT in Q1 2024 and has held it in 10 quarters since. The position peaked at $31.7M in Q4 2025. 57 funds tracked by Wall St. Rank hold BBOT as of Q2 2026.

  • Ken Griffin held 2,617,827 shares of BridgeBio Oncology worth $19.9M as of Q2 2026.
  • Ken Griffin bought 89,065 BridgeBio Oncology shares in Q2 2026, an estimated $743K.
  • BridgeBio Oncology made up ﹤0.01% of Ken Griffin's portfolio in Q2 2026, its #2591 holding.
  • Ken Griffin first reported a position in BridgeBio Oncology in Q1 2024 and has held it in 10 quarters since.
  • Ken Griffin's BridgeBio Oncology position peaked at $31.7M in Q4 2025.
  • 57 funds tracked by Wall St. Rank held BridgeBio Oncology as of Q2 2026.

Based on Citadel Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.